{"id":"NCT05896761","sponsor":"ViiV Healthcare","briefTitle":"A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants","officialTitle":"Sub-study to the A2M Study to Evaluate the Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in the A2M Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-28","primaryCompletion":"2022-08-23","completion":"2022-08-23","firstPosted":"2023-06-09","resultsPosted":"2023-09-18","lastUpdate":"2023-09-18"},"enrollment":118,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Type 1 (HIV-1)"],"interventions":[{"type":"DRUG","name":"Cabotegravir Injectable Suspension","otherNames":[]},{"type":"DRUG","name":"Rilpivirine Injectable Suspension","otherNames":[]}],"arms":[{"label":"Participants receiving CAB LA 400 milligrams (mg) and RPV LA 600 mg","type":"EXPERIMENTAL"},{"label":"Participants receiving CAB LA 600 mg and RPV LA 900 mg","type":"EXPERIMENTAL"}],"summary":"This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS2M \\[A2M\\]) study (NCT03299049).","primaryOutcome":{"measure":"Concentration at End of Dosing Interval (Ctau) of CAB LA Following Administration of CAB LA + RPV LA Q8W","timeFrame":"Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)","effectByArm":[{"arm":"CAB+RPV Q8W First Thigh Injection","deltaMin":1.67,"sd":69.3},{"arm":"CAB+RPV Q8W Last Thigh Injection","deltaMin":1.61,"sd":55.5},{"arm":"CAB+RPV Q8W Pre-Thigh Gluteal Injection","deltaMin":1.81,"sd":51.6}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States","Argentina","Canada","Germany","Italy","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":["Injection site pain","COVID-19","Injection site discomfort","Injection site swelling","Fatigue"]}}